Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind active-placebo-controlled psilocybin-assisted psychotherapy feasibility, safety, and efficacy study in treatment-resistant obsessive-compulsive disorder
MOH_2022-06-21_011861Phase 2Not yet recruiting
- Sponsor
- פרופ רונן סגמן
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of psilocybin and alprazolam in obsessive compulsive disorder (OCD) (2 arms), sponsored by פרופ רונן סגמן. Primary endpoint: Reduction in obsessive-compulsive disorder symptoms. Planned start May 2022; status: not yet recruiting.
02
Drugs
psilocybinalprazolam
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on MOH_2022-06-21_011861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-06-21_011861.